Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Jan 1;399(10319):3-5.
doi: 10.1016/S0140-6736(21)02757-4. Epub 2021 Dec 6.

Mixing mRNA, adenoviral, and spike-adjuvant vaccines for protection against COVID-19

Christopher D Richardson  1
Affiliations
Comment

Mixing mRNA, adenoviral, and spike-adjuvant vaccines for protection against COVID-19

Christopher D Richardson. Lancet. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

I declare no competing interests.

Comment on

References

    1. Liu X, Shaw RH, Stuart ASV, et al. Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial. Lancet. 2021;398:856–869. - PMC - PubMed
    1. Hillus D, Schwarz T, Tober-Lau P, et al. Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunization with ChAdOx1 nCoV-19 and BNT162b2: a 623 prospective cohort study. Lancet Respir Med. 2021;9:1255–1265. - PMC - PubMed
    1. Borobia AM, Carcas AJ, Pérez-Olmeda M, et al. Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-lab randomised, controlled, phase 2 trial. Lancet. 2021;398:121–130. - PMC - PubMed
    1. Barros-Martins J, Hammerschmidt SI, Cossmann A, et al. Immune responses against SARS629 CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination. Nat Med. 2021;27:1525–1529. - PMC - PubMed
    1. Schmidt T, Klemis V, Schub D, et al. Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination. Nat Med. 2021;27:1530–1535. - PMC - PubMed